6991-10-2
6991-10-2
Chemical Structure
Swertisin
- CAS No.: 6991-10-2
- Formula:C22H22O10
- Molecular Weight:446.40
IUPAC Name: 5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one
InChIKey: ABRULANJVVJLFI-DGHBBABESA-N
SMILES: O=C1C=C(C2=CC=C(O)C=C2)OC3=CC(OC)=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=C13
Biological Activity: Swertisin is an oral adenosine A1 receptor antagonist and an SGLT2 inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Swertisin | 99.54% | Swertisin is an oral adenosine A1 receptor antagonist and an SGLT2 inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Swertisin (Standard) | ≥98% | Swertisin (Standard) is the analytical standard of Swertisin. This product is intended for research and analytical applications. Swertisin, a C-glucosylflavone isolated from Iris tectorum, is known to have antidiabetic, anti-inflammatory and antioxidant effects. Swertisin is an adenosine A1 receptor antagonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Oh HK, et al. Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice. J Psychopharmacol. 2017 Feb;31(2):250-259. [Content Brief]
- [2]. Gurprit Bhardwaj, et al. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy. Arch Biochem Biophys. 2021 Oct 15:710:108995. [Content Brief]
- [3]. Hong-Yan Xu, et al. Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim. J Ethnopharmacol. 2020 Jul 15:257:112787. [Content Brief]
